scholarly journals Leukocytoclastic Vasculitis after Long-Term Treatment with Sunitinib: A Case Report

2011 ◽  
Vol 4 (2) ◽  
pp. 385-391 ◽  
Author(s):  
Alexandra Karadimou ◽  
Magdalini Migou ◽  
Afroditi Economidi ◽  
Alexandros Stratigos ◽  
Christos Kittas ◽  
...  
Keyword(s):  
Case Report ◽  
Leukocytoclastic Vasculitis ◽  
Term Treatment ◽  
Long Term Treatment

scholarly journals Fresh frozen plasma as a source of plasminogen for ligneous conjunctivitis: Case report and a review of the literature

2021 ◽  
pp. 031-035
Author(s):  
Park Benjamin J ◽  
Camoriano David ◽  
Vital Mark C ◽  
Chévez-Barrios Patricia ◽  
Goosey John D ◽  
...  
Keyword(s):  
Case Report ◽  
Fresh Frozen Plasma ◽  
Term Treatment ◽  
Ligneous Conjunctivitis ◽  
Caucasian Girl ◽  
Long Term Treatment ◽  
Effective Option ◽  
Fresh Frozen ◽  
Frozen Plasma

Purpose: To describe management of a patient with ligneous conjunctivitis secondary to plasminogen deficiency and review the literature on treatment with plasminogen. Design: Interventional case report. Methods: A 6-year-old Caucasian girl developed ligneous conjunctivitis recalcitrant to debridement and treatment with topical cyclosporin A and steroids. The literature was reviewed regarding treatment of ligneous conjunctivitis with plasminogen. Results: The patient was treated with plasminogen containing drops derived from her father’s fresh frozen plasma. The ligneous conjunctivitis resolved, and the patient was managed on these drops for the following 8 years, initiating treatment for flares and tapering according to clinical response. Conclusions: Plasminogen drops concentrated from fresh frozen plasma are a safe and effective option for long-term treatment of ligneous conjunctivitis.

Idiopathic Recurrent Catatonia Needs Maintenance Lorazepam: Case Report and Review

2007 ◽  
Vol 41 (7) ◽  
pp. 625-627 ◽  
Author(s):  
Narayana Manjunatha ◽  
Sahoo Saddichha ◽  
Christoday R.-J. Khess
Keyword(s):  
Case Report ◽  
Mood Disorders ◽  
Term Treatment ◽  
Down Regulation ◽  
Gaba A ◽  
Periodic Catatonia ◽  
Long Term Treatment ◽  
History Of ◽  
High Doses

Objectives: Catatonia as a phenomenon has been well described with either a schizophrenic illness, severe mood disorders or periodic catatonia disorder. We aim to report a patient who had recurrent catatonia that responded to and required lorazepam for maintenance. Methods: We describe the case of a 28 year old woman who had a history of recurrent catatonia that was unresponsive to most anti-psychotics, but who responded to high doses of lorazepam and needed long-term lorazepam for maintenance. Results and Conclusion: Our patient met the criteria for a diagnosis of idiopathic catatonic disorder. Response to lorazepam suggests that a certain group of patients may require long-term treatment with lorazepam, especially those who may have down-regulation of GABA-A receptors.

Canadian Case Report of Erythema Nodosum Leprosum Successfully Treated with Prednisone and Thalidomide

2010 ◽  
Vol 14 (2) ◽  
pp. 95-99 ◽  
Author(s):  
Mélissa Saber ◽  
Caroline Bourassa-Fulop ◽  
Danielle Bouffard ◽  
Nathalie Provost
Keyword(s):  
Case Report ◽  
Erythema Nodosum ◽  
Term Treatment ◽  
Response To Treatment ◽  
Cutaneous Lesions ◽  
Erythema Nodosum Leprosum ◽  
Long Term Treatment ◽  
The Face ◽  
Systemic Symptoms

Background: Erythema nodosum leprosum (ENL) is a disease rarely encountered in Canada. It is characterized by multiple remissions and recurrences, often requires long-term treatment, and can result in debilitating sequelae. Objective: To promote rapid recognition and adequate therapy for ENL. Methods: Case report of a 39-year-old man diagnosed with an ENL. The clinical and histopathologic features, treatment provided, and response to treatment are detailed in this article. Results: ENL presented itself as painful cutaneous lesions on the face and limbs, bilateral paresthesia of the fourth and fifth fingers, and systemic symptoms. Prednisone 40 mg daily for a week and then 60 mg daily for another week reduced the lesions by 80% and the pain by 50%. Although prednisone 60 mg daily was continued for one more week and then stopped, thalidomide was started at a dose of 300 mg daily for 4 weeks and then reduced gradually, which led to complete resolution. Conclusion: At the 7½-month follow-up, the patient remained completely asymptomatic.

scholarly journals Long-Term Disease Control by Pomalidomide-/Dexamethasone-Based Therapy in a Patient with Advanced Multiple Myeloma: A Case Report and Review of the Literature

2015 ◽  
Vol 8 (1) ◽  
pp. 189-195 ◽  
Author(s):  
Sophia Danhof ◽  
Martin Schreder ◽  
Susanne Strifler ◽  
Hermann Einsele ◽  
Stefan Knop
Keyword(s):  
Multiple Myeloma ◽  
Case Report ◽  
Proteasome Inhibitors ◽  
Progression Free Survival ◽  
Infectious Complications ◽  
Term Treatment ◽  
Novel Agents ◽  
Virus Reactivation ◽  
Long Term Treatment

Background: Therapy for multiple myeloma (MM) has substantially improved in the era of immunomodulatory drugs and bortezomib. However, the prognosis of patients with progressive disease despite treatment with these ‘novel agents' remains poor. Recently, pomalidomide was approved in this setting, but a median progression-free survival of <4 months still leaves room for improvement. Pomalidomide-based combination therapies are currently under investigation, but data on long-term treatment are lacking. Case Report: We present the case of a 68-year-old woman with refractory MM who received pomalidomide in combination with various drugs including anthracyclines, alkylators and proteasome inhibitors. Initially, major hematological toxicities and infectious complications including a hepatitis B virus reactivation were encountered. With careful dose adjustments and selection of combination partners, pomalidomide treatment was maintained for over 4 years and led to a sustained partial remission. In particular, the well-tolerated regimen of bortezomib, cyclophosphamide and dexamethasone together with pomalidomide was administered for >30 cycles. Conclusion: This case illustrates the value of an individualized approach to myeloma care given an increasing availability of ‘novel agents'. Tailored treatment using these drugs as a backbone is essential to achieve long-lasting responses and minimize side effects.

Sign in / Sign up

Export Citation Format

Share Document